Abstract
This is a review of pharmacotherapy in children and adolescents with mental retardation from the perspective of DSM and ICD disorders. The existing research is reviewed in young people with mental retardation but, when data are lacking, we examined the literature from adults with mental retardation and from typicallydeveloping children. The literature is discussed for each of the following disorders: ADHD, anxiety disorders, bipolar disorder, conduct disorder, depression, enuresis, schizophrenia, self injury, and tics and movement disorders. With the possible exception of ADHD, there is a woeful lack of empirical data on most of these disorders in young people with mental retardation. Clinicians will often be forced to extrapolate from data on adults having mental retardation and from typicallydeveloping children. The best policy is probäbly to treat such patients cautiously, while gathering data on the effects of such therapy in the hopes of beginning a data base.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aman MG (1987) (Guest editorial) Overview of pharmacotherapy: current status and future directions. Journal of Mental Deficiency Research 31: 121–130
Aman MG (1991) Assessing psychopathology and behavior problems in persons with mental retardation: a review of available instruments. (DHHS Publication No. [ADM] 91–1712). U.S. Department of Health and Human Services. Rockville, MD
Aman MG (1993) Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Annals of Clinical Psychiatry 5: 171–188
Aman MG (1996) Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities 8: 347–365
Aman MG, Findling RL, Derivan A, Merriman U, Conduct Study Group (2000) Risperidone vs place bo for serere conduct disorder in children with mental retardation. Poster presented at Collegium Internationale Neuro-psychopharmacologium (XXXIInd CINP Congress). Brussels
Aman M, Arnold E, Armstrong S (1999) Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 5: 279–289
American Psychiatric Association (1990) Benzodiazepine dependence, toxicity, and abuse: a task force report. Washington DC: American Psychiatric Press
Arnold LE, Gadow K, Pearson DA, Varley CK (1998) Stimulants. In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, OH, pp 229–257
Barkley RA, DuPaul GJ, Connor AF (1999) Stimulants. In: Werry JS, Aman MG (Eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. 2nd edn. Plenum Medical. New York, pp 213–247
Baumeister AA, Sevin JA, King BH (1998) Neuroleptics. In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, OH, pp 133–150
Blackwell B, Currah J (1973) The psychopharmacology of nocturnal enuresis. In: Kolvin I, McKeith R, Meadow S (Eds) Bladder Control and Enuresis. Heinemann, London
Bodfish MH, McCuller JW, Madison WR, Register, JM, Mailman M, Lewis RB, Mark H (1997) Placebo, double-blind evaluation of long-term naltrexone treatment effects for adults with mental retardation and selfinjury. Journal of Developmental and Physical Disabilities 9: 135–152
Bond S, Mandos L, Kurtz MB (1989) Midazolam for agressivity and violence in three mentally retarded patients. American Journal of Psychiatry 146: 925–926
Bryan DP, Herjanic B (1980) Depression and suicide among adolescents and young adults with selective handicapping conditions. Education Quarterly 1: 57–65
Buitelaar JK (1993) Self-injurious behaviour in retarded children: clinical phenomena and biological mechanisms. Acta Paedopsychiatrica 56: 105–111
Campbell M, Anderson LT, Small AM, Adams, Gonzalez N, Ernst M (1993) Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry 32: 1283–1291
Campbell M, Gonzalez NM (1996) Overview of neuroleptic use in child psychiatric disorders. Washington, D.C., American Psychiatric Press, Inc., USA xxiv, pp 215ff
Cohen JM, Ihrig SA, Lott K, Kerrick RS (1998) Risperidone for aggression and selfinjurious behavior in adults with mental retardation. Journal of Autism and Developmental Disorders 28: 229–233
Craft MJ, Schiff AA (1980) Psychiatric disturbance in mentally handicapped patients. British Journal of Psychiatry 137: 250–255
Cunningham MA, Pillai V, Blanchford-Rogers WJ (1968) Haloperidol in the treatment of children with severe behavior disorders. British Journal of Psychiatry 114: 845–854
DeLong GR, Aldershot AL (1987) Longterm experience with lithium treatment in childhood: correlation with clinical diagnosis. Journal of American Academy of Child and Adolescent Psychiatry 26: 389–394
Dosen A (1982) Ervaringen met psychofarmaca bij zwakzinnige kindern. Tijschrifft Kindersgeneeskunde 50: 10–19
Dosen A (1990) Psychische en gedragsstoornissen bij zwakssinnigen. Boom, Amsterdam
Dostal T, Zvolsky P (1970) Antiaggressive effects of lithium salts in severe mentally retarded adolescents. International Pharmacopsychiatry 5: 203–207
Einfeld SL, Aman MG (1995) Issues in the taxonomy of psychopathology in children and adolescents with mental retardation. Journal of Autism and Developmental Disorders 25: 143–167
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody TJ, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 54: 1031–1037
Francis A (2000) Expert consensus guideline series: Treatment of psychiatric and behavioral problems in mental retardation (special issue). American Journal on Mental Retardation 105: 159–228
Gillberg C, Aman MG, Reiss AL (1998) Fenfluramine. In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, OH, pp 303–310
Glue P (1989) Rapid cycling affective disorders in the mentally retarded. Biological Psychiatry 26: 250–256
Goetzl U, Grunberg F, Berkowitz B (1977) Lithium carbonate in the management of hyperactive aggressive behavior of the mentally retarded. Comprehensive Psychiatry 18: 599–606
Gross EJ, Hull HB, Lytton GJ, Hill JA, Pienel WC (1993) Case study of neuroleptic-induced akathisia: important implications for people with mental retardation. American Journal on Mental Retardation 98: 156–164
Gualtieri T, Schroeder SR (1989) Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis. Psychopharmacology Bulletin 25: 364–371
Handen BL (1993) Pharmacotherapy in mental retardation and autism. School Psychology Review 22: 162–183
Horrigan JL, Barnhill JP (1997) Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders 27: 313–323
Hucker SJ (1975) Pubertal manic depressive psychosis and mental subnormality — a case report. British Journal of Mental Subnormality 21: 34–37
Kastner T, Friedman DL, Plummer A (1990) Valproic acid for the treatment of children with mental retardation and mood symptomatology. Pediatrics 86: 467–472
Krakowski AJ (1963) Chlordiazepoxide in treatment of children with emotional disturbances. New York State Journal of Medicine 63: 3388–3392
LaVeck GD, Buckley P (1961) The use of psychopharmacological agents in retarded children with behavior disorders. Journal of Chronic Diseases 13: 174–183
Leckman JF, Harden MT, Riddle MA, Stevenson J, Ort S, Cohen DJ (1991) Clonidine treatment of Gilles de la Tourette’s syndrome. Archives of General Psychiatry 48: 324–328
Linter CM (1987) Short-cycle manicdepressive psychosis in a mentally handicapped child without family history. British Journal of Psychiatry 151: 554–555
Lott SA, Kerrick RS, Cohen JM (1996) Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacology Bulletin 32: 721–729
Menolascino FJ, Ruedrich SL, Golden CJ, Wilson JE (1985) Diagnosis and pharmacotherapy of schizophrenia in the retarded. Psychopharmacology Bulletin 21: 316–322
Moffatt MEK, Harlos S, Kirshen AJ, Burd L (1993) Desmopessin acetate and nocturnal enuresis: how much do we know? Pediatrics 92: 420–425
Naylor GD, Donald JM, LePoidevin D, Reid AH (1974) A double-blind trial of long-term lithium therapy in mental defectives. British Journal of Psychiatry 124: 52–57
Polizos P, Engelhart DM (1978) Dyskinetic phenomena in children treated with psychotropic medications. Pharmacology Bulletin 14: 65–68
Quay HC (1987) Patterns of delinquent behavior. In: Quay HD (Ed) Handbook of Juvenile Delinquency. Wiley, New York, pp 118–138
Ratey JJ, Sovner R, Parks A, Rogentine K (1991) Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple baseline, placebo lead-in study. Journal of Clinical Psychiatry 52: 159–162
Reid AD, Naylor GJ, Ka D (1981) A double-blind place bo controlled cross over trial of carbamazepine in overactive severely mentally handicapped patients. Psychological Medicine 11: 109–113
Remschmidt H (1976) The psychotropic effects of carbamazepine in nonepileptic patients, with particular reference to problems posed by clinical studies in children with behavioural disorders. In: Birkmayer W (Ed) Epileptic Seizures-Behaviour-Pain. Hans Huber, Bern, pp 253–258
Rett A (1968) Der verwendung von trimeprimin in der kinderheikunde. Medizinische Welt 47: 2616
Richardson MA, Haugland G, Craig TJ (1991) Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent patients. American Journal of Psychiatry 148: 1322–1328
Rinck C (1998) Epidemiology and psychoactive medication In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center. Columbus, OH, pp 31–44
Rivinus TM, Harmatz JS (1979) Diagnosis and lithium treatment of affective disorders in the retarded: five case studies. American Journal of Psychiatry 136: 551–554
Rojahn J (1994) Epidemiology and topographic taxonomy of self-injurious behavior. In: Thompson T, Gray DB (Eds) Destructive Behavior in Developmental Disabilities: Diagnosis and Treatment. Thousand Oaks, CA, Sage pp 49–67
Ruedrich S (1993) Treatment of bipolar mood disorder in persons with mental retardation. In: Fletcher RJ, Dosen A (Eds) Mental Health Aspects of Mental Retardation: Progress in Assessment and Treatment. New York, Lexington, pp 111–129
Sajatovic M, Ramirez LF, Kenny JT, Meltzer HY (1994) The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry 35: 29–33
Sandman CA, Thompson T, Barrett R, Verhoeven WM, McCubbin JA, Schroeder SR, Hetrick WP (1998) Opiate blockers. In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, OH, pp 291–302
Schmitt BD (1997) Nocturnal enuresis. Pediatrics in Review 18: 183–190
Schroeder SR, Breese GR, Muller RA (1990) Dopaminergic mechanisms in selfinjurious behavior. In: Routh DK, Wolraich M (Eds) Advances in Developmental and Behavioral Pediatrics. Jessica Kingsley Publishers, London, pp 181–198
Shapiro AK, Shapiro E, Fulop G (1989) Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Archives of General Psychiatry 46: 722–730
Smith EH, Gonzalez R (1967) Nortriptyline hydrochloride in the treatment of enuresis in mentally retarded boys. American Journal of Mental Deficiency 71: 825
Sovner R (1989) The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. Journal of Clinical Psychiatry 50: 40–43
Sovner R, Pary RJ, Dosen A, Gedye A, Barrera FJ, Cantwell DP, Huessy HR (1998) Antidepressant drugs. In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center. Columbus, OH, pp 179–200
Szymanski LS, King B, Goldberg B, Reid AH, Tonge BJ, Cain N (1998) Diagnosis of mental disorders in people with mental retardation In: Reiss S, Aman MG (Eds) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, OH, pp 3–17
Turner TH (1989) Schizophrenia and mental handicap: a historical review, with implications for further research. Psychological Medicine 19: 301–314
Viesselman JO (1999) Antidepressant and antimanic drugs. In: Werry JS, Aman MG (Eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. 2nd edn. Plenum Medical, New York, pp 249–296
Vining EP, Carpenter RO, Aman MG (1999) Antiepileptics (Anticonvulsants). In: Werry JS, Aman MG (Eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. 2nd edn. Plenum Medical, New York, pp 355–385
Whittier MC, West SA, Galli VB, Raute NJ (1995) Valproic acid for dysphoric mania in a mentally retarded adolescent. Journal of Clinical Psychiatry 56: 590–591
Willemsen-Swenkels SH, Buitelaar JK, Nijhof GJ, van England H (1995) Failure of naltrexone hydrochloride to reduce selfinjurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry 52: 766–773
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aman, M.G., Collier-Crespin, A. & Lindsay, R.L. Pharmacotherapy of disorders in mental retardation. European Child & Adolescent Psychiatry 9 (Suppl 1), S98–S107 (2000). https://doi.org/10.1007/s007870070023
Issue Date:
DOI: https://doi.org/10.1007/s007870070023